These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 8492939)

  • 1. Relapse in Guillain-Barré syndrome after treatment with human immune globulin.
    Irani DN; Cornblath DR; Chaudhry V; Borel C; Hanley DF
    Neurology; 1993 May; 43(5):872-5. PubMed ID: 8492939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human immune globulin infusion in Guillain-Barré syndrome: worsening during and after treatment.
    Castro LH; Ropper AH
    Neurology; 1993 May; 43(5):1034-6. PubMed ID: 8492921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group.
    van der Meché FG; Schmitz PI
    N Engl J Med; 1992 Apr; 326(17):1123-9. PubMed ID: 1552913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of high-dose intravenous immunoglobulins in Guillain-Barré syndrome.
    Rajah A
    Anaesthesia; 1992 Mar; 47(3):220-2. PubMed ID: 1566990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Guillain-Barré syndrome treated with high doses of immunoglobulins by the intravenous route: 4 cases].
    Uldry PA; Bogousslavsky J; Regli F
    Rev Neurol (Paris); 1991; 147(8-9):573-6. PubMed ID: 1962066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefit of intravenously administered immune serum globulin in patients with Guillain-Barré syndrome.
    Shahar E; Murphy EG; Roifman CM
    J Pediatr; 1990 Jan; 116(1):141-4. PubMed ID: 2295955
    [No Abstract]   [Full Text] [Related]  

  • 7. Intravenous immune globulin is also an efficient therapy of acute Guillain-Barré syndrome in affected children.
    Vallée L; Dulac O; Nuyts JP; Leclerc F; Vamecq J
    Neuropediatrics; 1993 Aug; 24(4):235-6. PubMed ID: 8232785
    [No Abstract]   [Full Text] [Related]  

  • 8. Relapses in the Guillain-Barré syndrome after treatment with intravenous immune globulin or plasma exchange.
    Romano JG; Rotta FT; Potter P; Rosenfeld V; Santibanez R; Rocha B; Bradley WG
    Muscle Nerve; 1998 Oct; 21(10):1327-30. PubMed ID: 9736064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe Guillain-Barré syndrome in childhood treated with human immune globulin.
    Reisin RC; Pociecha J; Rodriguez E; Massaro ME; Arroyo HA; Fejerman N
    Pediatr Neurol; 1996 May; 14(4):308-12. PubMed ID: 8805174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Initial experiences in the use of intravenous immunoglobulins in Guillain-Barré-Strohl syndrome].
    Ceccarelli M; Pifferi M; Simoni F; Lupetti L; Ughi C
    Pediatr Med Chir; 1987; 9(6):719-21. PubMed ID: 3444744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Guillain-Barré syndrome with high-dose immune globulins combined with methylprednisolone: a pilot study. The Dutch Guillain-Barré Study Group.
    Ann Neurol; 1994 Jun; 35(6):749-52. PubMed ID: 8210234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of repeated intravenous immunoglobulin in severe unresponsive Guillain-Barré syndrome.
    Farcas P; Avnun L; Frisher S; Herishanu YO; Wirguin I
    Lancet; 1997 Dec; 350(9093):1747. PubMed ID: 9413468
    [No Abstract]   [Full Text] [Related]  

  • 13. Guillain-Barré syndrome without sensory loss (acute motor neuropathy). A subgroup with specific clinical, electrodiagnostic and laboratory features. Dutch Guillain-Barré Study Group.
    Visser LH; Van der Meché FG; Van Doorn PA; Meulstee J; Jacobs BC; Oomes PG; Kleyweg RP; Meulstee J
    Brain; 1995 Aug; 118 ( Pt 4)():841-7. PubMed ID: 7655882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoglobulins in the treatment of Guillain-Barré syndrome in early childhood.
    al-Qudah AA
    J Child Neurol; 1994 Apr; 9(2):178-80. PubMed ID: 8006371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapy of acute Guillain-Barré syndrome. A national multicenter study].
    Kloss TM; Haupt WF; Philipp T; Diener HC
    Nervenarzt; 1994 Dec; 65(12):881-3. PubMed ID: 7854512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous immune globulin versus plasma exchange in Guillain-Barré syndrome.
    Raphael JC; Chastang C; Chevret S; Gajdos P
    N Engl J Med; 1992 Sep; 327(11):816; author reply 817. PubMed ID: 1501669
    [No Abstract]   [Full Text] [Related]  

  • 17. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group.
    Lancet; 1997 Jan; 349(9047):225-30. PubMed ID: 9014908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A case of Guillain-Barré syndrome treated with plasma exchange and intravenous high-dose immune globulin].
    Imai N; Miyata K; Terayama Y; Ishihara N
    Rinsho Shinkeigaku; 1997 Jun; 37(6):520-2. PubMed ID: 9366182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment related fluctuations in Guillain-Barré syndrome after high-dose immunoglobulins or plasma-exchange.
    Kleyweg RP; van der Meché FG
    J Neurol Neurosurg Psychiatry; 1991 Nov; 54(11):957-60. PubMed ID: 1800666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for treatment related clinical fluctuations in Guillain-Barré syndrome. Dutch Guillain-Barré study group.
    Visser LH; van der Meché FG; Meulstee J; van Doorn PA
    J Neurol Neurosurg Psychiatry; 1998 Feb; 64(2):242-4. PubMed ID: 9489539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.